Investors
Invest in ReNewVax
ReNewVax Ltd is a next-generation vaccine company which uses a novel platform technology for rational vaccine design, based on the concept of reverse vaccinology, incorporating high-throughput large-scale genomic analysis and ex vivo human predictive models to generate novel antigens against some of the most critical bacterial pathogens.
Our lead program, RVX-001, is entering IND-enabling studies, with first-in-human trials scheduled. ReNewVax’s pipeline contains two further programmes, RVX-002 and RVX-003, targeted at major global pathogens Streptococcus agalactiae and Streptococcus pyogenes.
Request Pitchdeck
